ClinicalTrials.gg
RecruitingNCT02087852Updated Apr 9, 2026

Kidney Cancer DNA Registry

An observational study in Renal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 9 under way, none of them phase 3. Kidney Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2014
the only one that year
Observational
3 of 35
2 open now
Registered
30th of 35
by date

Among the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the only one that started in 2014, is one of 3 observational ones, and was the 30th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

4 of the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

This registry will help us develop better methods of:

  • Preventing these cancers
  • Diagnosing these cancers
  • Treating these cancers
03

Conditions studied

  • Renal Cancer

Browse trials for

Keywords

  • Questionnaire
  • DNA
  • saliva
  • kidney cancer
  • 13-218
  • high risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Urologists, clinical geneticists, and medical oncologists at MSKCC, along with study personnel will identify patients, family members, and unaffected controls that may be eligible for the registry. Patients and families may also be directly referred to the MSKCC study team by any MSKCC physician, external physician, or by the family itself.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Kidney Cancer Case Cohort:

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must have a diagnosis or suspicion of kidney cancer

Family Member Cohort:

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required.

Control Cohort:

  • Must be ≥ 18 years of age AND
  • Must be an English-speaker AND
  • Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND
  • Must not be a blood relative of any cases or controls enrolled in this study

Exclusion criteria

Exclusion Criteria:

  • Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
750 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • kidney cancer patients receiving care at MSKCC

    Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.

    Other: salvia for germline DNA · Behavioral: the Kidney Cancer Questionnaire · Behavioral: Family History Questionnaire (when applicable) · Other: Blood draw · Behavioral: Epidemiologic Questionnaire

  • relatives of patients with kidney cancer

    Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.

    Other: salvia for germline DNA · Behavioral: the Kidney Cancer Questionnaire · Behavioral: Family History Questionnaire (when applicable)

  • healthy controls who are unrelated & do not have hx of cancer

    Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.

    Other: salvia for germline DNA · Behavioral: the Kidney Cancer Questionnaire · Behavioral: Family History Questionnaire (when applicable)

  • high risk

    Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation

    Other: salvia for germline DNA · Behavioral: Family History Questionnaire (when applicable) · Other: Blood draw · Behavioral: Epidemiologic Questionnaire

Interventions

  • Othersalvia for germline DNA
  • Behavioralthe Kidney Cancer Questionnaire

    Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.

  • BehavioralFamily History Questionnaire (when applicable)

    Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.

  • OtherBlood draw
  • BehavioralEpidemiologic Questionnaire

    Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.

06

What researchers measure

Primary outcomes

  1. establish a kidney cancer registry

    with detailed epidemiologic data and germline DNA available for next generation sequencing from consenting patients, selected family members, and healthy unrelated controls.

    Time frame: 5 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
  • Memorial Sloan Kettering Monmouth (Consent and Follow up)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
  • Memorial Sloan Kettering Bergen (Consent and Follow up )
    Montvale, New Jersey 07645, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
  • Memorial Sloan Kettering Commack (Consent and Follow-up)
    Commack, New York 11725, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
  • Memorial Sloan Kettering Westchester (Consent and Follow up)
    Harrison, New York 10604, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
    • Kenneth Offit, MD · Contact646-888-4050
    • Jonathan Coleman, MD · Principal investigator
  • Memorial Sloan Kettering Nassau (Consent and Follow-Up)
    Uniondale, New York 11553, United States
    Recruiting
    • Jonathan Coleman, MD · Contact646-422-4432
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2027 and a completion of Mar 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 14, 2014
Start
Mar 2014
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02087852
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Mar 2014
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Jonathan Coleman, MD
Contact
646-422-4432
Kenneth Offit, MD
Contact
646-888-4050
Jonathan Jonathan, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion